From: John Younger <jyounger@newviewsurg.com> Date: Fri, Jul 21, 2023, 6:56 PM Subject: New View Surgical pausing most commercial operations, exploring alternative paths forward To: John Younger <jyounger@newviewsurg.com>

Dear Shareholders,

I hope this letter finds you in good health and spirits. I'm writing to inform you about a significant decision the board of directors and management have had to make regarding the future of our company.

As you are aware, over the past several months we've been carrying out a detailed assessment of both the commercial readiness of New View's lead product, the VisionPort, and the commercial opportunity likely available to it upon its delayed return to human use. We've also carefully considered the company's current cash position, its projected capital needs in the next 18 months, and the fund-raising environment in which additional investment would be pursued.

The judgement of the Board given the totality of this assessment is that New View Surgical is unlikely to be commercially viable with its current product.

We have therefore decided to preserve our remaining capital by ceasing most commercial operations and seeking alternative plans for moving forward. This includes investigating other means of monetizing the company's assets.

This was not an easy decision, and it was not taken lightly. On behalf of myself and New View Surgical, I want to extend our gratitude for your support and trust in our company. Your investment has been instrumental, and we have strived to deliver value to our shareholders at every step.

We will be holding an investor update zoom call at 10:00 am on Wednesday, July 26<sup>th</sup> to provide more details and answer any questions regarding the company's next steps. In preparation for that call, please forward to me any questions you have. Note that I'm also happy to address additional or follow up questions on the call Wednesday morning.

Sincerely,

John G Younger, MD

Interim CEO

New View Surgical, Inc.

jyounger@newviewsurg.com